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Antimicrobial resistance (AMR) is mak-
ing the clinical management of infections
such as gonorrhoea increasingly difficult
worldwide [1–3]. In between the discovery
of penicillin and the emergence of multi-
drug resistant (MDR-NG) and extensively
drug resistant (XDR-NG) strains [4,5],
gonorrhoea was considered unpleasant,
but not particularly serious, because it
was easily treated [4–7]. Experts increas-
ingly describe N. gonorrhoeae as becoming
an untreatable superbug [2,4,7] because of
reports of MDR-NG and XDR-NG
strains resulting in treatment failures with
extended spectrum cephalosporins (ESCs),
such as cefixime and ceftriaxone, from
Europe, North America, Asia, and Africa
[7–9]. The World Health Organization
(WHO) estimated that there were 106
million new uncomplicated gonococcal
infections worldwide in 2008, the majority
of cases in places with limited diagnostic
and treatment options. If these infections
become untreatable then complications,
including pelvic inflammatory disease,
ectopic pregnancy, tubal infertility, neo-
natal eye infections, and consequences
such as facilitation of HIV co-transmis-
sion, will become more common [2,5].
The emergence of ESC resistance has
coincided with the rapid expansion of
molecular diagnostic testing for gonor-
rhoea (Figure 1). PCR is an invention that
revolutionised diagnostic testing in infec-
tious diseases, as in many other fields of
medicine. Diagnostic tests that amplify
specific DNA or RNA sequences are
known collectively as nucleic acid ampli-
fication tests (NAATs) and include PCR.
The benefits of NAATs for pathogen
detection are widely recognised [1]. There
are now commercially available NAATs
for rapid detection of tuberculosis, includ-
ing rifampicin resistance [10], and for
methicillin resistant Staphylococcus aureus
(MRSA) and its main resistance gene
[11]. Experience with rapid molecular
diagnostics shows that the potential health
gains are determined not by the technol-
ogy but by its successful implementation in
a diagnostic process [11,12]. For tubercu-
losis, the time to diagnosis could be
shortened from weeks to hours if the rapid
test can be placed at the point of care.
At present, culture-based antimicrobial
susceptibility testing is still needed because
the specificity of the rapid NAATs is too
low to allow definitive decisions about
treatment of either tuberculosis [10] or
MRSA [11]. Mathematical modelling
suggests that the impact of rapid molecular
diagnosis of tuberculosis in high HIV
prevalence areas might be less than
anticipated because the major gain is in
early detection of less infectious smear-
negative tuberculosis and the large reser-
voir of latent infection remains undetected
[13].
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Summary Points
N Antimicrobial resistance and overuse of antimicrobials are serious threats to the
treatment of gonorrhoea.
N Neisseria gonorrhoeae susceptibility to extended spectrum cephalosporins is
decreasing and treatment failures are spreading, but no new drug class is
licensed to replace them for immediate treatment.
N Nucleic acid amplification tests are increasingly used to diagnose gonorrhoea
but current commercially available tests do not detect antimicrobial resistance.
N Tests for gonorrhoea that allow individually tailored antimicrobial therapy at
the first contact with health services will need to be point-of-care tests that can
be integrated into the diagnostic process to give accurate results in around an
hour.
N Development of nucleic acid amplification tests that incorporate rapid
detection of N. gonorrhoeae and its resistance determinants and ensuring the
rational use of antimicrobials are priorities for controlling both gonorrhoea and
antimicrobial resistance.
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The limitations of molecular diagnostic
tests for sexually transmitted infections are
less widely publicised and tend to focus on
diagnostic test performance issues [14–17].
In this Essay we discuss the benefits and
disadvantages of molecular diagnosis of N.
gonorrhoeae in the context of AMR and the
implications of AMR for gonorrhoea
treatment recommendations.
Current Management of
Gonorrhoea
Prompt and appropriate treatment for
patients with gonorrhoea and their sexual
partners at the first contact with health
services is the priority, endorsed by
international guidelines [18]. Delaying
treatment to wait for diagnostic and
antimicrobial susceptibility results is unac-
ceptable for three reasons. First, urethritis,
the most common clinical presentation in
men, can cause purulent urethral dis-
charge and severe pain, typically described
as ‘‘pissing glass’’ [19]. Second, sexual
partners of people with diagnosed gonor-
rhoea have a very high risk of being
infected [20]; rapid treatment is especially
important for preventing re-infection and
reducing onward transmission in groups
with the highest rates of sexual partner
change and AMR gonorrhoea, such as
men who have sex with men and sex
workers. Third, most gonococcal infec-
tions are diagnosed in settings with no, or
limited, diagnostic facilities. WHO syn-
dromic management flow charts recom-
mend empirical antimicrobial treatment
that should cure 95% or more cases of the
most common causes of the syndrome [18].
The syndromic approach is reasonably
accurate for the management of gonococ-
cal urethritis in men but does not work well
for cervical gonorrhoea in women or rectal
gonorrhoea in men who have sex with men
and women because most of these infec-
tions are asymptomatic [21]. Immediate
treatment for symptomatic infections is a
useful strategy when antimicrobials can be
replaced once the cure rate falls below the
threshold. But overuse of antimicrobials is
now a serious problem for gonorrhoea
because ESCs are ‘‘last-line’’ antimicrobials
and no new drug classes are licensed to
replace them [2,7].
Where laboratory facilities are available,
culture is a sensitive method for the
diagnosis of genital N. gonorrhoeae infections
and is completely specific if adequate
confirmatory tests are done [20]. N. gonor-
rhoeae has fastidious growth requirements so
highly nutritious selective culture media are
needed (Table 1). Antimicrobial suscepti-
bility can then be tested on cultured isolates
but is, unfortunately, not always done. The
laboratory tests for culture and susceptibil-
ity take 48 hours in total. Strengthening
culture-based surveillance of local AMR
patterns is an increasingly important tool
for the detection of resistant strains and
monitoring their spread [2], even if routine
culture facilities are not available.
Advantages of Molecular
Diagnostics for Gonorrhoea
There is no commercially available test
for gonorrhoea that gives both same-day
diagnosis and an antimicrobial susceptibil-
ity profile forN. gonorrhoeae. But the ability of
NAATs to detect tiny amounts of nucleic
acid has several advantages over culture for
the diagnosis of an N. gonorrhoeae infection.
First, specimens for NAATs are easier to
transport and store because they do not
need the organism to be viable for
detection. Second, NAATs can be auto-
mated and multiplexed detecting both
Chlamydia trachomatis and N. gonorrhoeae,
which is useful because both organisms
cause similar clinical syndromes. Third,
analysis can be done on non-invasive self-
collected specimens like urine and vaginal
swabs. These qualities mean that testing is
easier in remote areas and can be extended
to groups who were previously hard to
reach but at high risk of both infection and
AMR, such as men who have sex with men
[3]. Fourth, NAATs are more sensitive
than culture methods in general and
particularly for asymptomatic infections in
the pharynx and rectum (although no
internationally available commercial NAAT
has licensing approval for use on extra-
genital samples) [22].
NAATs for N. gonorrhoeae diagnosis
became available in the early 1990s [22]
and are now the most common method
used for gonorrhoea diagnosis in many
countries, including the UK (Figure 1) and
US [23]. The sharp increase in the
number of diagnosed gonorrhoea cases
since 2010 (Figure 1) is likely to be
associated, in part, with both higher
numbers of tests and the higher sensitivity
of NAAT. In the US, the absolute number
of gonorrhoea tests, estimated from data
from manufacturers, increased from 2000
to 2004 but the percentage of tests that
were done by culture fell [23].
Figure 1. Trend in number of cases of gonorrhoea diagnosed, NAAT testing for
gonorrhoea, and selected antimicrobial resistance in genitourinary medicine clinics in
England and Wales. Cases of gonorrhoea are from Public Health England; percentages of tests
done using NAATs are from UK audits of asymptomatic patients in genitourinary medicine clinics
(http://www.bashh.org/BASHH/BASHH_Groups/National_Audit_Group/BASHH/BASHH_Groups/
National_Audit_Group.aspx?hkey= c17918b8-5c72-40bd-981f-632f89e45708). Percentage of iso-
lates resistant to ciprofloxacin and cefixime are from reference [1] and the 2012 report of the UK
Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP, http://www.hpa.org.
uk/Topics/InfectiousDiseases/InfectionsAZ/Gonorrhoea/AntimicrobialResistance/), with values ob-
tained using PlotDigitizer software (http://plotdigitizer.sourceforge.net/).
doi:10.1371/journal.pmed.1001598.g001
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Disadvantages of Molecular
Diagnostics for Gonorrhoea
NAATs do not routinely provide
information about antimicrobial
susceptibility of N. gonorrhoeae
Many of the limitations of NAATs for
gonorrhoea diagnosis are the flip-side of
their advantages. The main limitation for
clinical management is that there is no
viable organism so NAATs cannot provide
data about minimum inhibitory concen-
trations for antimicrobials, which guide
therapy [2,3,7,14,24]. If the health care
professional takes a culture specimen and
requests antimicrobial susceptibility testing
that shows that the organism is resistant to
the antibiotic prescribed, they can recall
the patient within 2 to 3 days and
prescribe individually tailored antibiotics.
Or, if the culture-based test on an
asymptomatic patient is positive, antimi-
crobial susceptibility testing allows specific
antimicrobial therapy to be prescribed. All
results from NAAT-diagnosed gonococcal
infections have to be treated ‘‘blind’’ and
commercially available NAATs do not
currently detect any AMR determinants,
so more NAAT-diagnosed than culture-
diagnosed infections will be unnecessarily
treated with ESC-based regimens.
Molecular methods for AMR N. gonor-
rhoeae could give results faster (2–3 hours)
than culture-based testing (48 hours). But
the actual turnaround time, from ordering
the test to changing patient care, is not
much faster if the molecular test is run on
batched samples once a day or every other
day [11]. Tests for gonorrhoea that allow
individually tailored antimicrobial therapy
at the first contact with health services will
need to be point-of-care tests with an
actual turnaround time of around an hour
[25]. The weak correlation between N.
gonorrhoeae genetic resistance determinants,
minimum inhibitory concentrations of
ESC, and treatment outcome currently
makes it difficult to use genetic markers to
guide therapy for gonorrhoea [7].
The first documented case of XDR-NG
was diagnosed in a Japanese female sex
worker who had a pharyngeal infection
diagnosed initially by NAAT. A culture
specimen was obtained two weeks later
when she returned for treatment but there
was no post-treatment culture specimen
and she was lost to follow-up for three
months, after receiving a second dose of
ceftriaxone for presumed treatment failure
diagnosed by NAAT [4,26]. This case
report shows how detection of AMR and
treatment failure in NAAT-diagnosed
gonorrhoea infections can be delayed.
AMR will only be detected if the patient
returns for a follow-up visit and a culture
specimen is taken or if the patient returns
with persistent symptoms. But antimicro-
bial resistant infections can persist asymp-
tomatically. Pharyngeal gonorrhoea is
often asymptomatic, might require higher
doses of antibiotics to cure it [5], and is the
location that is most difficult to diagnose
by culture because of growth of other
bacterial species and low bacterial load
[27]. Many patients with gonorrhoea do
not attend for a follow-up visit at all [28].
Resistant strains of gonorrhoea can there-
fore spread undetected if patients have not
had a culture specimen taken at initial
presentation and do not attend for follow-
up.
NAATs encourage over-testing and
overtreatment of gonorrhoea
Simplified specimen collection and mul-
tiplex testing have disadvantages. Over-
testing is facilitated by simultaneous testing
for N. gonorrhoeae on specimens taken for
chlamydia screening in populations at low
risk of gonorrhoea such as asymptomatic
heterosexual adults tested in primary care
[15]. In such settings, the predictive value
of a positive test for gonorrhoea can be
unacceptably low [14,17], meaning that
most people with a positive test are not
infected. Overtreatment will occur if
clinicians interpret initial positive gonor-
rhoea NAAT results as diagnosed infec-
tions without supporting information from
a sexual history and/or a confirmatory
test, as recommended [14,20]. The nega-
tive consequences of false-positive diagno-
sis of gonorrhoea in a low risk population
include breakdown of previously stable
monogamous relationships [14]. Whilst
some NAATs for N. gonorrhoeae show very
high specificity [29], their performance is
inherently limited by genetic sequence
variation between subtypes and cross-
reactions with related Neisseria species
[22]. Overtreatment also has consequenc-
es for AMR. Unnecessary use of extended
spectrum antimicrobials, such as ceftria-
xone, increases the chances that commen-
sal Neisseria spp. develop resistance and that
resistance determinants will be transferred
horizontally to N. gonorrhoeae [22,30].
The cost of NAAT for gonorrhoea
diagnosis
The high cost of NAATs can result in
over-testing or under-testing, depending
Table 1. Advantages and disadvantages of molecular diagnostic testing for gonorrhoea in relation to culture and antimicrobial
susceptibility testing.
Characteristic Advantage of NAATs Disadvantage of NAATs
Ease of testing Can be done on non-invasive and self-collected specimens. More testing in low risk populations; low positive predictive
value results in unnecessary treatment and potential harm
to personal relationships.
Case detection More cases diagnosed. More accessible testing for hard to
reach groups at high risk of infection, e.g., sex workers,
men who have sex with men.
Gains in increased case detection over culture could be
offset if treating more cases results in more people who are
susceptible to re-infection.
Test performance More sensitive than culture, especially in pharyngeal, rectal,
and asymptomatic infections.
Specificity decreased by cross-reactions and other
sequence-related issues.
Laboratory requirements Automation allows high throughput, reduces contamination. Expensive equipment and specialised training required.
AMR In-house assays detect some AMR mutations and resistant
strains.
No current antimicrobial susceptibility testing in commercial
tests; Complete AMR testing cannot be performed.
Treatment failure Detection relies on clinical treatment failure or a late test of
cure.
Licensing approval Approved for endocervical, vaginal, urethral, urine
specimens
Not approved for pharyngeal or rectal specimens but can be
used if laboratory evaluation satisfactory.
doi:10.1371/journal.pmed.1001598.t001
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on who has to pay for the test and who
makes the profit. Over-testing with
NAATs occurs if health care systems
reimburse laboratories for the number of
analytic targets. Laboratories can charge
twice for a NAAT to detect N. gonorrhoeae
and C. trachomatis even if the tests are done
simultaneously in the same automated
procedure [15]. Under-testing can occur
if the patient has to pay an out of pocket
contribution, e.g., in primary care in the
Netherlands (J van Bergen, 02.07.2013,
personal communication) and in the Swiss
health system (D. Oertle, 03.07.2013,
personal communication). Patients at high
risk of sexually transmitted infections
might be unwilling to have check-ups if
they are asymptomatic. Patients with
symptoms might decline laboratory testing
and opt for syndromic treatment with
antimicrobials to cover the most common
causative organisms. In the latter situation,
blind antibiotic treatment and loss to
follow-up could exacerbate the spread of
AMR, which will, however, be undetected.
Antimicrobial prescribing for
gonorrhoea and AMR
Antimicrobial prescribing policies can
also contribute to the emergence of AMR
gonorrhoea [2,7,24]. Single dose oral
treatment with a single class of antimicro-
bials is a goal of selecting drugs for
sexually transmitted infections, including
gonorrhoea [2] to aid adherence to
recommended regimens by both patients
and health care professionals [24]. Mono-
therapy, however, exerts selection pressure
for resistance to emerge [24]. The WHO
criterion for selecting regimens for which
microbial resistance is ‘‘unlikely to develop
or can be delayed’’ [2] is probably
incompatible with the desire for single
dose oral monotherapy. Efficacy of at least
95% is required for a first line antimicro-
bial that will be used for empiric treatment
[2]. Cefixime was the last available single
dose oral treatment and AMR surveillance
data show that this no longer has the
required level of efficacy (Figure 1). Clin-
ical guidelines in Europe [20] and the US
[31] now recommend combination treat-
ment with intramuscular ceftriaxone and
oral azithromycin. The addition of azith-
romycin is to delay the emergence of
resistance to ESC [20,24,31]. High level
resistance to azithromycin monotherapy
has already emerged in the treatment of
gonorrhoea, syphilis, chancroid, and My-
coplasma genitalium and experts have called
for its use to treat all bacterial sexually
transmitted infections to be limited [24].
The Role of Molecular Diagnosis
in the Spread and Control of
Drug Resistant Gonorrhoea
Could the expansion of NAAT diagno-
sis for gonorrhoea exacerbate the continu-
ing spread of AMR gonorrhoea? There is
no definitive answer to this question yet
but there are issues that should be
investigated further, given the global
increase in AMR, the lack of new first
line antimicrobials for gonorrhoea treat-
ment [1], and the continued expansion of
NAAT at the expense of culture-based
testing [2,7,23]. Countries with strong
gonococcal antimicrobial surveillance sys-
tems and antimicrobial stewardship poli-
cies can mitigate the potentially negative
impacts of a diagnostic shift to NAATs [3].
But misuse and abuse of antimicrobials are
widespread in many countries, and there is
no strong surveillance of AMR, even in
Japan where AMR is often detected first
[5].
Another reasonable question is whether
diagnostic test manufacturers, regulators,
and researchers should have considered
the implications that NAATs for gonor-
rhoea diagnosis might have on AMR
before promoting and expanding their
use so widely. The benefits of NAAT
diagnosis for sexually transmitted infec-
tions often consider gonorrhoea and
chlamydia together. The gains in sensitiv-
ity and technical complexity of NAATs
compared to culture are smaller for N.
gonorrhoeae diagnosis than for C. trachomatis
[14], and AMR in chlamydia remains
largely unexplored [24]. Early descriptions
of commercial NAAT development for N.
gonorrhoeae do not appear to mention the
inability to give AMR data as a potential
problem [32]. This is surprising as gono-
coccal resistance was already a global
public health issue at the time of develop-
ment.
Academic research groups have devel-
oped in-house molecular tests for one or
more genetic determinants of AMR N.
gonorrhoeae [33–35]. But very few of these
tests detect mutations associated with [36],
or strains exhibiting [37], ESC resistance,
which is the imminent threat. The ongoing
evolution of ESC resistance, involving
combinations of mutations in several
genes, is a major challenge for test
development. Tests that need continual
updating with new target sequences are
unlikely to be profitable for diagnostics
companies in the short term. Supranation-
al initiatives to invest in non-profit re-
search might therefore be needed to
overcome some of the challenges of
feasibility and commercial viability.
Conclusions
Current knowledge and practice about
the use of NAAT for gonorrhoea diagnosis
could be improved in several ways. First,
all national and international guidelines
about the use of NAAT for gonorrhoea
diagnosis should specify situations in
which culture-based testing and tests of
cure are needed; transport media that can
be used for both NAAT and culture will
facilitate this. The cost of additional testing
should be borne by the health system
because the information about AMR
would be used for the public health good.
Second, in the absence of empirical
diagnostic trials, mathematical modelling
will be needed to explore the impact of
NAAT-based rapid tests for the detection
of AMR gonorrhoea on the spread of
resistance and on clinical outcomes. Dy-
namic transmission models can capture
the net effects of competing factors such as
increased detection and treatment of
gonorrhoea, increased re-infection risk,
and reduced or delayed detection of
AMR on the transmission of gonorrhoea
and of resistant strains. Third, clinicians
should follow international guidelines for
the early detection of ESC resistant
gonorrhoea and clinical treatment failure,
which take into account the role of NAAT
diagnosis [2]. Fourth, the development of
molecular tests to detect gonococcal resis-
tance mutations should become part of the
solution [1,2,7,25]. Commercial diagnos-
tics companies should invest more to
develop and evaluate NAATs that detect
both N. gonorrhoeae and AMR determinants
reliably, particularly in resource poor
settings. The true cost of ignoring gono-
coccal AMR will include the costs of
treating the infection and its complications
as experienced in the pre-antibiotic era
[38]. AMR gonorrhoea needs to be
conceptualised and tackled as part of the
global problem of resistance [1,2] with
strong proactive programs for phenotypic
AMR surveillance to monitor and even
pre-empt the emergence of critical levels of
AMR [3]. Improving the capabilities of
NAAT diagnosis for gonorrhoea and
ensuring their rational use is a priority
for controlling both gonorrhoea and
AMR.
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